欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - Имуносупресори - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Множествена миелома - Антинеопластични средства - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - Множествена миелома - Антинеопластични средства - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.